8/12/2011

The NIH's National Institute of Allergy and Infectious Disease awarded a $2.8 million grant to Kineta to develop drugs against RNA viruses, including hepatitis and flu. "Our goal is to find novel drugs that can treat infections for the long term," said Kristen Bedard, the firm's principal scientist in virology.

Related Summaries